UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy

The Journal of molecular diagnostics : JMD, 2019-07, Vol.21 (4), p.553-571

2019

Volltextzugriff (PDF)

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers

Journal of thoracic oncology, 2016-03, Vol.11 (3), p.414-419

2016

Volltextzugriff (PDF)

Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.1474-1482

2018

Volltextzugriff (PDF)

Epithelioid GBMs show a high percentage of BRAF V600E mutation

The American journal of surgical pathology, 2013-05, Vol.37 (5), p.685-698

2013

Volltextzugriff (PDF)

DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer

Journal of thoracic oncology, 2019-04, Vol.14 (4), p.737-741

2019

Volltextzugriff (PDF)

Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

Journal of thoracic oncology, 2016-08, Vol.11 (8), p.1293-1304

2016

Volltextzugriff (PDF)

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

PloS one, 2013-12, Vol.8 (12), p.e82236

2013

Volltextzugriff (PDF)

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Journal of thoracic oncology, 2019-09, Vol.14 (9), p.1666-1671

2019

Volltextzugriff (PDF)

Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non-small Cell Lung Cancer

Clinical cancer research, 2018-07, Vol.24 (14), p.3334-3347

2018

Volltextzugriff (PDF)

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-04, Vol.372 (18), p.1700-1709

2015

Volltextzugriff (PDF)

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2012-12, Vol.7 (12), p.1807-1814

2012

Volltextzugriff (PDF)

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer

Clinical cancer research, 2018-06, Vol.24 (12), p.2758-2770

2018

Volltextzugriff (PDF)

Identifying and Targeting ROS1 Gene Fusions in Non―Small Cell Lung Cancer

Clinical cancer research, 2012-09, Vol.18 (17), p.4570-4579

2012

Volltextzugriff (PDF)

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

Journal of thoracic oncology, 2015-05, Vol.10 (5), p.768-777

2015

Volltextzugriff (PDF)

The Revised College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline: A Step Forward for Molecular Cytopathology

Archives of pathology & laboratory medicine (1976), 2018-06, Vol.142 (6), p.684-685

Aisner, Dara L

2018

Volltextzugriff (PDF)

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Archives of pathology & laboratory medicine (1976), 2018-03, Vol.142 (3), p.321-346

2018

Volltextzugriff (PDF)

Targeting the WNT Signaling Pathway in Cancer Therapeutics

The oncologist (Dayton, Ohio), 2015-10, Vol.20 (10), p.1189-1198

2015

Volltextzugriff (PDF)

Molecular Pathology of Non-Small Cell Lung Cancer: A Practical Guide

American journal of clinical pathology, 2012-09, Vol.138 (3), p.332-346

2012

Volltextzugriff (PDF)

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

Cancer discovery, 2015-10, Vol.5 (10), p.1049-1057

2015

Volltextzugriff (PDF)

Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer

Cancer, 2019-04, Vol.125 (7), p.1038-1049

2019

Volltextzugriff (PDF)

Wake Up and Smell the Fusions: Single-Modality Molecular Testing Misses Drivers

Clinical cancer research, 2019-08, Vol.25 (15), p.4586-4588

2019

Volltextzugriff (PDF)

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

Cancer, 2012-09, Vol.118 (18), p.4502-4511

2012

Volltextzugriff (PDF)

Rapid On-Site Evaluation of Endobronchial Ultrasound-Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society

Archives of pathology & laboratory medicine (1976), 2018-02, Vol.142 (2), p.253-262

2018

Volltextzugriff (PDF)

1 – 25 von 210

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(196)
Mit Volltextzugriff
(172)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(126)
Life Sciences & Biomedicine
(123)
Humans
(107)
Oncology
(71)
Female
(48)
Pathology
(48)
Male
(46)
Middle Aged
(37)
Lung Neoplasms - Genetics
(35)
Mutation
(34)
Adult
(32)
Aged
(29)
Lung Cancer
(28)
Lung Neoplasms - Pathology
(26)
Carcinoma, Non-Small-Cell Lung - Genetics
(25)
Lung Neoplasms - Drug Therapy
(24)
Medical Laboratory Technology
(23)
Respiratory System
(22)
Carcinoma, Non-Small-Cell Lung - Pathology
(20)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(18)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers

Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples

Epithelioid GBMs show a high percentage of BRAF V600E mutation

DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer

Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non-small Cell Lung Cancer

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer

Identifying and Targeting ROS1 Gene Fusions in Non―Small Cell Lung Cancer

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

The Revised College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline: A Step Forward for Molecular Cytopathology

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Targeting the WNT Signaling Pathway in Cancer Therapeutics

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

Molecular Pathology of Non-Small Cell Lung Cancer: A Practical Guide

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer

Wake Up and Smell the Fusions: Single-Modality Molecular Testing Misses Drivers

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

Rapid On-Site Evaluation of Endobronchial Ultrasound-Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society

Suchergebnisse filtern